IND

Abbisko Therapeutics · ABSK061

Abbisko Therapeutics Announces IND Clearance from the CDE for ABSK061, a Highly Selective FGFR2/3 Inhibitor, for the Treatment of Achondroplasia

Abbisko Therapeutics Co., Ltd. has announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the IND application for ABSK061, a highly…

Read More Abbisko Therapeutics Announces IND Clearance from the CDE for ABSK061, a Highly Selective FGFR2/3 Inhibitor, for the Treatment of Achondroplasia
BEACH301 · Clinical Trial · Tyra Biosciences · TYRA-300

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

– TYRA-300 is the first oral FGFR-3 selective inhibitor to be well-tolerated in clinical studies – – First child with achondroplasia expected to be dosed in Q1 2025 – CARLSBAD,…

Read More Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

translate ?